Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-2103 vs Paclitaxel in Advanced NSCLC (STELLAR 3)
NCT00054210Phase 3Terminated
- Sponsor
- CTI BioPharma Corp.
- Start
- Jan 2003
- Primary completion
- Oct 2004
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of paclitaxel poliglumex in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Overall Survival. Started Jan 2003; status: terminated.
02
Drugs
paclitaxel poliglumex
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00054210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054210.